

# Three Doses to Finish: A Review on Completion of Human Papillomavirus (HPV) Vaccination among Adolescent Females Aged 12-17 years

Abeer Arain<sup>1</sup>

Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma, USA

**Corresponding author:** Abeer Arain, MD, PhD, Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma, USA. Email: abeer-arain@ouhsc.edu

**Rec date:** 12/15/2018 **Acc date:** 12/15/2018 **Pub date:** 12/15/2018

**Copyright:** © 2018 Abeer Arain, MD, PhD. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

**Purpose:** The purpose of this review is to evaluate the completion rates of HPV vaccination among adolescent females aged 12-17 years. **Methods:** A search of the literature was conducted using the keywords "HPV vaccination", "adolescent females", and "completion rates". **Results:** The completion rates of HPV vaccination among adolescent females aged 12-17 years range from 10% to 80%. **Conclusion:** The completion rates of HPV vaccination among adolescent females aged 12-17 years are low. **Keywords:** HPV vaccination, adolescent females, completion rates.

**Keywords:** Cervical cancer; HPV; Vaccine; Adolescent females; Intervention

## Risk Factors of the Disease

Some of the most important risk factors of cervical cancer includes early age at first sexual intercourse, infection with Human Papillomavirus, multiple sexual partners, active and passive cigarette smoking, high parity, prolonged use of oral contraceptives (>5 years) [6]. Human Papilloma virus causes almost all cases of cervical cancer. It also causes some non-cervical cancers like vulvar, vaginal, anal, and penile and oropharyngeal cancer [7]. For cervical cancer, the rate of HPV transmission increases with the increase in number of sexual partners, multiparity and early age at first sexual experience [8].

## The Burden of Cervical Cancer

Cancer is the leading cause of death in developed countries and second leading cause of death in developing world [1]. The burden of cancer is still increasing due to number of reasons including cigarette smoking, physical inactivity, unhealthy diets etc. Certain viruses like (EBV) Epstein Barr virus, (HPV) Human Papillomavirus and (HIV) Human Immunodeficiency virus also have the ability to cause cancer [2]. Although lung, breast and colorectal cancers are the leading cause of mortality among women, and cervical cancer still holds an important place in cancer causing mortality among females [3].

## Screening for Cervical Cancer

High quality screening methods for cervical cancer, such as Papanicolaou smear cytology testing (Pap smear) has significantly reduced the morbidity and mortality from squamous cell carcinoma of the cervix that constitutes 90% of all cervical cancers [9]. This reduction in mortality is due to increased detection of the advance disease in early stages, and the detection of pre-invasive lesions that reduces the overall incidence of invasive cancer [5]. It is very much understood now that persistent infection with Human Papillomavirus (HPV) is necessary for the development of cervical cancer. 10 Different subtypes of HPV, like HPV 16 and HPV 18 are highly carcinogenic genotypes, and can cause cervical cancer. Thus cervical carcinogenesis proceeds as: acquiring Human Papillomavirus, persistent infection of HPV, progression of the disease to precancerous stage, and the stage of invasive disease [5,10,11].

Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of mortality in females in the world, contributes to about 9% of the total new cancer cases and 8% of total number of deaths due to cancer among women [4]. Estimates of worldwide burden of cervical cancer indicates that 529,800 cases and 275,100 deaths occur due to cervical cancer every year [2].

The highest incidence rates of cervical cancer are seen in Eastern and Southern Africa [3]. India, accounts for about 27% of all the disease cases of cervical cancer. In United States, the incidence of cervical cancer is getting decreased [3]. However it is still found to show high incidence rates in Hispanics, 4 and African American ethnicities of the country [5]. The incidence rate of cervical cancer is 34% higher and the mortality rate is double in African American women when compared to White American females [4]. Hispanic women in United States show incidence and mortality from cervical cancer about 50-70 times higher than non-Hispanic white females [5].

The importance of cervical cancer screening lies in the fact that one half of cervical cancers in the US are in women who have never been screened. About 10% of cervical cancer 12 Mwhoa

years [14]. For women in the age range of 21-29 years, screening for

sexual life [37], another set of parents in the survey, regarded the vaccine as unnecessary, which is something frightening for public health professionals [37]. In North Carolina, lack of HPV vaccine completion was found to be higher among teenagers who are not very compliant about their routine visit to their doctor [38]. According to Schluterman et al. [39] HPV vaccine completion was low among African-American female teens compared to Caucasians in their study [39], and population that had public health insurance showed better

Papillomavirus infection and its dangerous outcomes, to educate mothers and daughters about the HPV vaccine, its access, and increase the awareness among the targeted population about vaccine's doses and the importance of completing all the doses before the onset of sexual activity; 2) to promote and increase the adherence to vaccines multi-dose regimen.

## Health Promotion Setting for Intervention and the Target Audience

*Three doses to finish*, is proposed as a school based intervention that can target any public school of the country. The education about HPV infection, its vaccination and the importance of adherence to the regimen can best be delivered at the school. The school is selected as

23. Dunne EF, Unger ER, Stenberg M (2007) Prevalence of HPV infection among females in the United States. *JAMA* 297(8): 813-819
24. Centers for Disease Control and Prevention (2012) Recommended immunization schedules for persons aged 0 through 18 years- United States. *MMWR Morb Mortal Wkly Rep* 61(5): 1-4
25. Neuzil KM, Canh G, Thiem VD (2011) Immunogenicity and reactivity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized non-inferiority trial. *JAMA* 305(14): 1424-1431.
26. Kohli M, Ferko N, Martin A (2007) Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. *Bj JCancer* 96(1): 143-150
27. Onuki M, Matsumoto K, Satoh T (2009) Human Papillomavirus infections among Japanese women: age-related prevalence and type specific risk for cervical cancer. *Cancer Sci* 100(7): 1312-1316
28. Centers for Disease Control and Prevention (2008) National, state and local area vaccinated coverage among adolescents aged 13-17 years- United States. *MMWR Morb Mortal Wkly Rep* 58: 997-1001.
29. Wong CA, Berkowitz Z, Dorell CG, Price RA (2008) Human papillomavirus vaccine uptake among 9 to 17 year-old-girls. *National Health and Nutrition Examination Survey. Cancer* 117: 5612-20
30. Laz TH, Rahman M, Berenson AB (2012) An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States. *National Health Interview Survey. Vaccine* 30: 3534-3540
31. Kepka D, Warner EL, Kinney AY (2015) Low human papillomavirus vaccine knowledge among Latino parents in Utah. *J Immigrant Minority Health* 17: 125-131.
32. Jain N, Euler GL, Shefer A (2009) Human Papillomavirus (HPV) awareness and vaccination initiation among women in the United States. *National Immunization Survey-Adult, Prev Med* 48: 426-431.
33. Staras SAS, Vadaparampil ST, Haderxhanaj LT, Shenkman EA (2010) Disparities in human papillomavirus vaccine series initiation among adolescent girls enrolled in Florida Medicaid Programs, 2006-2008. *J of Adolescent Health* 47: 381-388
34. Reiter PL, Katz ML, Paskett ED (2012) HPV vaccination among adolescent females from Appalachia: Implications for cervical cancer disparities. *Cancer Epidemiol Biomarkers Prev* 21(12). Doi: 10.1158/1055-9965.EPI-12-0850
35. McRee AL, Reiter PL, Brewer NT (2010) Vaccinating adolescent girls against human papillomavirus-Who decides? *Preventive Medicine* 50: 203-214
36. Madhivanan P, Srinivas V, Marlow L (2014) Indian Parents prefer vaccinating their daughters against HPV at older ages. *Asian Pacific Journal of Cancer Prevention* 15(1): 107-110
37. Darden PM, Thompson DM, Roberts JR (2013) Reasons for not vaccinating Adolescents: national Immunization Survey of Teens, 2008-2011. *Pediatrics* 131,645-651.
38. Moss JL, Gilkey MB, Reiter PL, Brewer NT (2012) Trends in HPV vaccine initiation among adolescent females in North Carolina, 2008-2010. *Cancer Epidemiol Biomarkers Prev* 21(11): 1913-22